Loading
A phase 2 trial of Avapritinib in systemic mastocytosis, run by Blueprint Medicines Corporation, active and no longer recruiting.
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis is a phase 2 interventional study registered as NCT03731260 by Blueprint Medicines Corporation, with 251 participants enrolled, started 2019-04-16 and due to reach its primary completion in 2027-06-23. Interventions recorded: Avapritinib, Placebo. Conditions listed: Indolent Systemic Mastocytosis. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Indolent and smouldering systemic mastocytosis, Systemic mastocytosis, Sanofi.
Shares Indolent and smouldering systemic mastocytosis, Systemic mastocytosis, Sanofi.
Shares Indolent and smouldering systemic mastocytosis, Avapritinib.
Shares Indolent and smouldering systemic mastocytosis, Systemic mastocytosis.
Shares Avapritinib, Systemic mastocytosis, Small-molecule kinase inhibitors.
Shares Avapritinib, Systemic mastocytosis.
Shares Sanofi, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/